Genentech sues Biogen for debt over blockbuster MS drug

Published Date: 08 Mar 2023

Roche's Genentech Inc sued Biogen MA Inc in federal court in San Francisco, alleging that Biogen owed additional patent royalties from worldwide sales of its blockbuster multiple sclerosis and Crohn's disease drug, Tysabri.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Pretreatment Liver Tests Often Overlooked in CDK4/6 Therapy

2.

Encounters matter in cancer care: Health care professionals can play a key role in restoring patients' sense of control

3.

Lentiviral Gene Therapy Shows Promise in Severe Hemophilia A

4.

Acalabrutinib + Venetoclax Combo Earns FDA Nod for CLL

5.

Prostate cancer death risk is higher in late teens and early 20s weight gain.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot